Journal profile · Medicine-General Medicine
Clinical and Translational Discovery
ISSN 2768-0622 · Wiley · Australia
Clinical and Translational Discovery: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 3.1 (journal website); fully open access; APC about USD 2,420; median 57 days to acceptance (80 articles, last 24 months); acceptance rate 58% (journal website); 86 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Clinical and Translational Discovery is published by Wiley and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Extracellular vesicles in disease, Cancer Genomics and Diagnostics and Single-cell and spatial transcriptomics, together about 24.3% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Clinical and Translational Discovery aims at being the world-leading communication channel of science related to gene and protein-based structure and function, regulation and editing, detection and diagnosis, analysis and intelligence, imaging and therapy, and ethics and regulations. Clinical and Translational Discovery is a journal covering all aspects on clinical and translational medicine-associated discovery and development to publish the high-quality, peer-reviewed research articles, reviews, editorials, commentaries, and short communications. Clinical and Translational Discovery covers topics dedicated to the interaction and intercommunication between cells, genes, proteins, transcriptional networks, genome constructions, structures, functions, and regulations; and to the advance of gene- and protein-based editing, detection, diagnosis, analysis, intelligence, imaging, therapy, and ethics. The journal focuses on the early phase of bench to bedside approach, favoring studies and clinical observations which generate hypotheses and questions relevant to the patient and disease, and guide the investigations of clinical and translational medicine. Indexing information: Biological Abstracts (Clarivate Analytics) BIOSIS Previews (Clarivate Analytics) CAS: Chemical Abstracts Service (ACS) Directory of Open Access Journals (DOAJ) Emerging Sources Citation Index (Clarivate Analytics) SCOPUS (Elsevier) Web of Science (Clarivate Analytics)
From the journal's Aims & Scope
Research area (LetPub): Medicine-General Medicine
Editor-in-chief Diane Catherine WangPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology8.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology8.3%
- Single-cell and spatial transcriptomicsBiochemistry, Genetics and Molecular Biology7.5%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology6%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.2%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.2%
- Cancer Immunotherapy and BiomarkersMedicine4.8%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.1Publisher website ·
- Impact factor (publisher) 2025
- 3.1Publisher website ·
- CiteScore 2026-06
- 2.8LetPub ·
- CiteScore (publisher)
- 2.8Publisher website ·
- CiteScore (publisher) 2025
- 2.8Publisher website ·
- SJR 2026-06
- 0.49LetPub ·
- SNIP 2026-06
- 0.3LetPub ·
- h-index
- 17OpenAlex ·
- i10-index
- 37OpenAlex ·
- 2-year mean citedness
- 1.54OpenAlex ·
- Self-citation rate
- 3.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 43LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 72Publisher website ·
- Downloads per year (publisher) 2025
- 136,057Publisher website ·
Articles by year OpenAlex count · 546 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 99 | 99 | 14 |
| 2025 | 86 | 86 | 97 |
| 2024 | 112 | 112 | 347 |
| 2023 | 95 | 95 | 358 |
| 2022 | 142 | 142 | 396 |
| 2021 | 12 | 12 | 52 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
57 daysMedian, submission to acceptance · P25–P75 32 days – 85 days
- Acceptance to online
- median 12 days (80 articles)
- Submission to online
- median 75 days
- Sample
- 80 articles with submission and acceptance dates (191 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Acceptance rate (publisher)
- 58%Publisher website ·
- Acceptance rate (publisher) 2025
- 58%Publisher website ·
- Submission to first decision
- 14 daysPublisher website ·
- Submission to first decision 2025
- 14 daysPublisher website ·
- Submission to acceptance 2025
- 19 daysPublisher website ·
- Acceptance to publication 2025
- 14 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,040 / GBP 1,840 / USD 2,420 | Yes | CC BY | |
| OpenAlex | USD 2,420 / EUR 2,040 / GBP 1,840 | — | — | |
| LetPub | USD 2,300 / GBP 1,749 / EUR 1,943 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Understanding Open Access
As an open access journal, all articles in Clinical and Translational Discovery are freely available to read, download and share immediately on publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- Australia
- Language
- English
- ISSN
- 2768-0622
- Society / sponsor
- Shanghai
- Latest issue on the website
- Volume 6, Issue 5 (October 2026)
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical and Translational Discovery
What CAS zone is Clinical and Translational Discovery in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical and Translational Discovery?
The journal's website gives an impact factor of 3.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 2.8, h-index 17.
How long does peer review take at Clinical and Translational Discovery?
Based on the dates recorded on 80 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 57 days (interquartile range 32–85 days); authors report an average review time of about 10 weeks; the journal's website gives an acceptance rate of 58% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Clinical and Translational Discovery?
According to LetPub and DOAJ records, Clinical and Translational Discovery is indexed in ESCI, Scopus and DOAJ.
Is Clinical and Translational Discovery open access, and what is the APC?
Clinical and Translational Discovery is a fully open-access journal. APC about USD 2,420.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .